Cerezyme
Sanofi Gaucher drug approved in Europe
January 22, 2015Sales and Marketing Cerdelga, Cerezyme, Gaucher, Sanofi, eliglustat, imiglucerase
The European Commission has approved Sanofi-owned Genzyme’s Cerdelga for the treatment of Gaucher disease Type 1.Designed for a condition that …
Pfizer enters Gaucher disease market
May 3, 2012Sales and Marketing Cerezyme, Elelyso, Gaucher, Genzyme, Pfizer, Shire, Vpriv
Pfizer has gained FDA approval for its new Gaucher disease drug Elelyso. Elelyso (taliglucerase alfa) is an enzyme replacement therapy …
Genzyme to divest pharma intermediates business
February 8, 2011Manufacturing and Production Cerezyme, Corden Pharma Switzerland, Corden Pharma group, Genzyme, International Chemical Investors Group, Sekisui Chemical Co, imiglucerase
Genzyme has agreed to sell off its pharmaceutical intermediates business to International Chemical Investors Group, a holding company which has …
Shire says new plant will add to Replagal, Vpriv capacity
January 17, 2011Manufacturing and Production Cerezyme, Replagal, Shire, Vpriv
UK drugmaker Shire has completed construction of a new manufacturing facility for its orphan disease drugs Replagal and Vpriv, and …
Pfizer submits Gaucher drug to EMA
November 29, 2010Sales and Marketing Cerezyme, EMA, Gaucher disease, Genzyme, Pfizer, Protalix BioTherapeutics, Shire, Vpriv, taliglucerase alfa
Pfizer and partner Protalix BioTherapeutics have submitted a marketing application to European regulator the EMA for their Gaucher disease candidate …
More woe for Genzyme as shipping delays continue
July 6, 2010Manufacturing and Production Cerezyme, Fabrazyme, Gaucher, Genzyme, manufacturing compliance
Genzyme is expecting further delays in shipments of two key products as it struggles to bring its troubled Allston Landing …
Genzyme confirms details of consent decree and $175m fine
May 27, 2010Manufacturing and Production Cerezyme, Fabrazyme, Genzyme, Lumizyme, Thyrogen, manufacturing compliance
Genzyme’s predictions on the penalties levied for the ongoing problems at its manufacturing facility in Allston Landing have been confirmed, …
Genzyme fined $175m for manufacturing problems
April 22, 2010Manufacturing and Production Cerezyme, Cerezyme Fabrazyme Gaucher's Genzyme, Fabrazyme, Gaucher's, Genzyme, manufacturing compliance
The FDA seems to have lost patience with biotechnology company Genzyme over contamination problems at its manufacturing facilities, levying a …
FDA flexes muscles over ailing Genzyme plant
March 29, 2010Manufacturing and Production Cerezyme, Fabrazyme, Gaucher, Genzyme, manufacturing compliance
Manufacturing compliance problems continue to weigh down US biotechnology company Genzyme, with the US Food and Drug Administration now saying …
Genzyme plays down Irish contamination
March 18, 2010Manufacturing and Production Cerezyme, Contamination, Fabrazyme, Genzyme
The contamination problems plaguing Genzyme in the US have also appeared in product manufactured at its plant in Waterford, Ireland, …
Shire launches Vpriv to capitalise on Genzyme woes
March 2, 2010Sales and Marketing Cerezyme, Gaucher's, Shire
Shire has gained US approval to launch Vpriv, its new treatment for Gaucher’s disease, which it hopes will steal market …
Shire readies Gaucher drug Vpriv
February 23, 2010Manufacturing and Production Cerezyme, Gaucher's, Shire, Vpriv
Shire Pharmaceuticals says it has already manufactured enough of its Vpriv to treat around 400 Gaucher disease patients and could …
Hospira helps Genzyme tackle manufacturing problems
January 6, 2010Manufacturing and Production Cerezyme, Fabrazyme, Genzyme, Hospira
Genzyme has taken the decision to move the fill and finish stages of its manufacturing process to Hospira in order …
Genzyme resumes Cerezyme supplies
December 3, 2009Manufacturing and Production Cerezyme
Genzyme has begun shipping newly produced Cerezyme manufactured at its Allston Landing plant for the first time after it was …
Shire files for Gaucher drug in Europe
December 1, 2009Sales and Marketing Cerezyme, Gaucher, Shire
Shire has followed up its marketing applications for Gaucher disease treatment velaglucerase alfa in the US and Canada with a …
